Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.40 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.40 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606205 | 0.93 | TP53 (0.45) | MTNR1AMTNR1BMAPTTP53ATM | |
| SCHEMBL5345349 | 0.88 | TRPA1 (0.43) | MAPTTP53ATMALDH1A1L3MBTL1 | |
| SCHEMBL13115367 | 0.87 | TRPA1 (0.42) | MAPTTP53ATMALDH1A1L3MBTL1 | |
| SCHEMBL13115590 | 0.84 | ATM (0.47) | ATM | |
| SCHEMBL5367271 | 0.83 | MTNR1A (0.53) | MTNR1AMTNR1BTP53ALDH1A1CDYL2 | |
| SCHEMBL3605821 | 0.83 | CCNE1 (0.43) | MAPTTP53ATML3MBTL1 | |
| SCHEMBL3602186 | 0.82 | TP53 (0.41) | MAPTTP53ALDH1A1P2RY12 | |
| SCHEMBL3597098 | 0.81 | KMT2A (0.42) | MAPTTP53ALDH1A1L3MBTL1 | |
| SCHEMBL3599700 | 0.79 | ATM (0.42) | MAPTTP53ATMALDH1A1 | |
| SCHEMBL13115365 | 0.77 | TRPV1 (0.46) | MAPTTP53ATMALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007115231-A2 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | MTNR1A 1079/4885MTNR1B 833/4885MAPT 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.